CME
NASH & Diabetes
- S1-E1 – Growing NAFLD-Diabetes Dual Prevalence Increases CVD Risk for Diabetics
  - S3-E1.1 – Fatty Liver Prevalence May Be Higher Than Previously Thought, Especially Among Type 2 Diabetes Patients
  - S3-E1.2 – NAFLD Prevalence and Type 2 Diabetes in an Endocrinology Clinic: The Need for Screening and Vigilance
NASH Tsunami
Events
- 2021 Events
Sponsorships
- Our Sponsors & Affiliates
- Sponsorship Programs
Surfers
Contact

CME
NASH & Diabetes
- S1-E1 – Growing NAFLD-Diabetes Dual Prevalence Increases CVD Risk for Diabetics
  - S3-E1.1 – Fatty Liver Prevalence May Be Higher Than Previously Thought, Especially Among Type 2 Diabetes Patients
  - S3-E1.2 – NAFLD Prevalence and Type 2 Diabetes in an Endocrinology Clinic: The Need for Screening and Vigilance
NASH Tsunami
Events
- 2021 Events
Sponsorships
- Our Sponsors & Affiliates
- Sponsorship Programs
Surfers
Contact

Category: FIB-4

All Podcast Categories

S3-E1.2 - NAFLD Prevalence and Type 2 Diabetes in an Endocrinology Clinic: The Need for Screening and Vigilance

S1-E1.2 – NAFLD Prevalence and Type 2 Diabetes in an Endocrinology Clinic: The Need for Screening and Vigilance

Fatty Liver Researcher and endocrinology key opinion leader Ken Cusi discusses the high levels of NAFLD prevalence and fibrosis among Type 2 Diabetes Mellitus patients and the value of early screening, particularly in endocrinology clinics, where the percent of patients with NAFLD and NASH fibrosis is double what we find in primary care.

June 21, 2022

Discussion Group

Join The Discussion in our LinkedIn or Facebook Discussion Groups

Facebook Linkedin

Join The Live Recordings

Recording for this session will take place at 3:15p Eastern US time (1900H CET, 1800H BT) on Monday.

Linkedin Facebook Twitter Instagram

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT

Stay In Touch

Apple Spotify Youtube

CME
NASH & Diabetes
- S1-E1 – Growing NAFLD-Diabetes Dual Prevalence Increases CVD Risk for Diabetics
  - S3-E1.1 – Fatty Liver Prevalence May Be Higher Than Previously Thought, Especially Among Type 2 Diabetes Patients
  - S3-E1.2 – NAFLD Prevalence and Type 2 Diabetes in an Endocrinology Clinic: The Need for Screening and Vigilance
NASH Tsunami
Events
- 2021 Events
Sponsorships
- Our Sponsors & Affiliates
- Sponsorship Programs
Surfers
Contact